Sermorelin, Tesamorelin & Other Options

Sermorelin is a 29-amino-acid peptide that represents the bioactive portion of natural GHRH. It was one of the first GH secretagogues available and has the longest clinical track record. Sermorelin stimulates the pituitary to produce and release GH through the same receptor as natural GHRH. Its effects are self-limiting: it cannot cause GH levels to exceed what the pituitary is capable of producing, providing a built-in safety mechanism. Typical dosing is 200-500mcg before bed. Sermorelin is often prescribed by anti-aging clinics as a well-established, FDA-studied option.

Tesamorelin is a GHRH analog with a trans-3-hexenoic acid modification that increases its potency and stability. It is the only GH secretagogue currently FDA-approved (for HIV-associated lipodystrophy). Clinical trials have shown it reduces visceral adipose tissue by 15-18% without affecting subcutaneous fat distribution, making it particularly valuable for individuals with metabolically dangerous visceral fat accumulation. It also improves cognitive function in older adults, possibly through IGF-1-mediated neuroplasticity. Tesamorelin is more potent than sermorelin but also more expensive.

MK-677 (Ibutamoren) deserves mention as it is widely discussed in the optimization community, though it is technically not a peptide but a small molecule ghrelin receptor agonist. MK-677 has the advantage of oral bioavailability (no injection needed) and produces sustained GH elevation over 24 hours. However, it also significantly increases appetite and can worsen insulin sensitivity with long-term use, making it a poor choice for individuals addressing insulin resistance (Root Cause 2). Most clinical experts consider the Ipamorelin + CJC-1295 stack superior to MK-677 for overall safety and efficacy, particularly in the context of the Three Root Causes framework.